ArticleLeukemia2021
CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.
Open access · hybridAbstract read
In one paragraph
Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- STAT3 as a Candidate Shared Regulator of the CXCR4/CXCL12 and CXCR5/CXCL13 Homing Axes in Chronic Lymphocytic Leukemia.International journal of molecular sciences · 2026Review
- Resistance pathways and next-generation treatments in chronic lymphocytic leukemia.Discover oncology · 2026Review
- The role of chemokine receptors in leukemia: implications for prognosis and therapeutic strategies.Molecular biology reports · 2026Review
- Physiological distribution and dosimetry of AlBMC medical imaging · 2026Article
- Molecular Features Accompanying Richter's Transformation in Patients with Chronic Lymphocytic Leukemia.International journal of molecular sciences · 2025Review
- [Establishment of a chronic lymphocytic leukemia mouse model via adoptive transfer of Eμ-TCL1 transgenic splenocytes].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Review
- Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?Cancers · 2024Review
- Proliferating CLL cells express high levels of CXCR4 and CD5.HemaSphere · 2024Article
- CXCR4 overexpression in chronic lymphocytic leukemia associates with poorer prognosis: A prospective, single-center, observational study.Genes and immunity · 2024Observational
- PET imaging of CXCR4 expression using [Theranostics · 2024Article
- B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia.Frontiers in oncology · 2024Review
- Biology and Treatment of Richter Transformation.Frontiers in oncology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 4 countries.
Richard LewisDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0002-2404-6703
H Carlo MaurerInternal Medicine II, School of Medicine, Technische Universität München, Munich, Germany.
Nikita SinghDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Irene Gonzalez-MenendezInstitute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, Eberhard Karls Universität Tübingen, Tübingen, Germany.
Matthias WirthDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0002-8340-0872
Markus SchickDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Le ZhangDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Konstandina IsaakidisDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Anna Katharina SchergerSchool of Medicine, Technische Universität München, Munich, Germany.
Veronika SchulzeDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Junyan LuEuropean Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Thorsten ZenzDepartment of Medical Oncology and Hematology, Universitätsspital and Universität Zürich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-7890-9845
Katja SteigerInstitute of Pathology, Technische Universität München, Munich, Germany.ORCID http://orcid.org/0000-0002-7269-5433
Roland RadTranslaTUM, Center for Translational Cancer Research, Technische Universität München, Munich, Germany.
Leticia Quintanilla-MartinezInstitute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, Eberhard Karls Universität Tübingen, Tübingen, Germany.
Marion EspeliUniversité de Paris, Institut de Recherche Saint-Louis, EMiLy, INSERM U1160, Paris, France.
Karl BalabanianUniversité de Paris, Institut de Recherche Saint-Louis, EMiLy, INSERM U1160, Paris, France.ORCID http://orcid.org/0000-0002-0534-3198
Ulrich Keller *Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. ulrich.keller@charite.de.ORCID http://orcid.org/0000-0002-8485-1958
Stefan Habringer *Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. stefan.habringer@charite.de.ORCID http://orcid.org/0000-0002-3976-9592
Humboldt-Universität zu Berlin · DETechnical University of Munich · DEGerman Cancer Research Center · DEUniversity of London Institute in Paris · FRUniversity of Tübingen · DEEuropean Molecular Biology Laboratory · DEUniversity of Zurich · CH
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant CXCR4 activity has been implicated in lymphoma pathogenesis, disease progression, and resistance to therapies. Using a mouse model with a gain-of-function CXCR4 mutation (CXCR4
Indexed as
Gene Expression Regulation, LeukemicMutationAnimalsCell Cycle ProteinsDisease ProgressionFemaleForkhead Box Protein M1Leukemia, Lymphocytic, Chronic, B-CellMaleMiceMice, Inbred C57BLMice, KnockoutPolo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsReceptors, CXCR4Cell Cycle ProteinsCXCR4 protein, mouseForkhead Box Protein M1Foxm1 protein, mousePolo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsReceptors, CXCR4Tcl1 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.